Sanofi

Recruiting

99 years and younger

All

Phase N/A

1 Location

Brief description of study

The dupilumab clinical program in EoE has provided evidence that long-term suppression of IL-4 and IL-13 could lead to progressive improvement in fibrostenosis. . There is a need for longer term assessments with comprehensive functional, histological, molecular, clinical, and endoscopic assessments to characterize the risk of fibrotic progression as well the potential for reversal with dupilumab.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 08 May 2024. Study ID: 854399

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).